top of page
PT-141-Vial.png

PT-141

PT-141: Peptide shown to enhance libido and sexual performance by directly activating arousal pathways.

⭐⭐⭐⭐⭐Clinically Proven Sexual Wellness Peptide

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram

Potential Benefits of PT-141 (Bremelanotide)

On-Demand Option

Used “as needed” rather than daily—fits around real life and avoids continuous exposure.

Desire & Arousal Support

FDA-approved for acquired, generalized HSDD in premenopausal women; non-hormonal mechanism.

Whole-Program Friendly

Pairs with coaching on stress, sleep, meds review, and relationship context for best outcomes.

PT-141 (brand device available) is indicated for premenopausal women with acquired, generalized HSDD. Not studied/approved for men or postmenopausal women for this indication. Use only under a licensed clinician’s supervision.

Contraindications & Precautions

Contraindications

  • Uncontrolled hypertension or known cardiovascular disease

  • Known hypersensitivity to bremelanotide or formulation components

  • Pregnancy or breastfeeding (insufficient safety data)

Use with Caution

  • Controlled hypertension—monitor; transient ↑BP/↓HR can occur for several hours

  • History of nausea/migraine—start when you can rest; anti-nausea plan if needed

  • Oral meds that must work quickly—PT-141 can slow gastric emptying

  • Oral naltrexone users: exposure may be reduced; discuss alternatives

  • Skin hyperpigmentation risk—may cause focal darkening (face, gums, breasts); usually resolves slowly or not at all after stopping

Outcomes, Dosing & Side Effects

What to Expect

  • Some patients report higher desire and reduced distress around low desire

  • Response varies—discontinue if no meaningful improvement after several uses (your clinician will guide)

  • Best results with a full plan: stress/sleep support, meds review, and relationship context

Dosing & Administration (On-Demand)

  • Dose: 1.75 mg subcutaneous injection using the on-demand device

  • Timing: At least ~45 minutes before anticipated sexual activity

  • Limits: ≤1 dose per 24 hours; ≤8 doses per month

  • Sites: Abdomen or thigh; rotate injection sites

Side Effects — Common

  • Nausea (sometimes significant), vomiting

  • Flushing, headache, dizziness, fatigue

  • Injection-site reactions

  • Transient ↑blood pressure and ↓heart rate

  • Focal hyperpigmentation with repeated use

Side Effects — Serious/Rare

  • Severe hypertension, syncope—seek care

  • Allergic reactions (rash, swelling, breathing difficulty)

  • Persistent or concerning mood changes

Why Choose PT-141?

PT-141 offers a non-hormonal, on-demand option for premenopausal women with acquired, generalized HSDD when used within a clinician-guided plan that addresses medical, psychological, and relationship factors.

Patient Story:
“Using it only when needed felt simple. Pairing it with stress and sleep coaching helped the most.” — Camila T.

Mechanism of Action

  • Melanocortin Agonist (MC4R): Acts centrally to modulate pathways tied to sexual desire and arousal

  • Non-Hormonal: Does not rely on estrogen/testosterone replacement

  • Gastric Emptying: Temporarily slows gastric emptying—may reduce exposure to certain oral meds

Educational content only; not a substitute for medical advice. Use PT-141 only under supervision of a licensed healthcare professional, and stop if you experience concerning side effects.

bottom of page